| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728222.12.1.1 |
| P698 | PubMed publication ID | 18076366 |
| P2093 | author name string | Wang Hui | |
| Andrew D Rowan | |||
| Gary J Litherland | |||
| Jennifer M Milner | |||
| P2860 | cites work | Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins | Q22009926 |
| Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family | Q22010479 | ||
| The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain | Q24293718 | ||
| PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? | Q24296651 | ||
| Biochemical characterization of human collagenase-3 | Q24318765 | ||
| MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes | Q24628843 | ||
| A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL | Q24799036 | ||
| Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors | Q24806147 | ||
| ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis | Q24810478 | ||
| Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption | Q24816674 | ||
| Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller | Q27732555 | ||
| Human and mouse proteases: a comparative genomic approach | Q28184208 | ||
| Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis | Q28190416 | ||
| Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65 | Q28213946 | ||
| Expression profiling of metalloproteinases and their inhibitors in cartilage | Q28239499 | ||
| c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis | Q28343409 | ||
| Inhibition of furin-like enzymes blocks interleukin-1alpha/oncostatin M-stimulated cartilage degradation | Q44398373 | ||
| Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. | Q44601270 | ||
| A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis | Q44643741 | ||
| Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment o | Q44725424 | ||
| Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element | Q44848225 | ||
| Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice | Q45034879 | ||
| Regulation of gelatinases expression by cytokines, endotoxin, and pharmacological agents in the human osteoarthritic knee | Q45129216 | ||
| Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. | Q45858376 | ||
| Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation | Q45879224 | ||
| Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils | Q46438744 | ||
| Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents | Q46742423 | ||
| Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors | Q46794470 | ||
| Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. | Q47321715 | ||
| Aggrecan protects cartilage collagen from proteolytic cleavage | Q47724408 | ||
| Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament | Q50491685 | ||
| Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. | Q52113450 | ||
| Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). | Q53554633 | ||
| Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. | Q53574209 | ||
| Suppression of NF-κB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis | Q58629377 | ||
| Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model | Q42047774 | ||
| Knockouts model the 100 best-selling drugs--will they model the next 100? | Q43436501 | ||
| Synovial collagenase: its presence in culture from joint disease of diverse etiology | Q43536575 | ||
| Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. | Q43805676 | ||
| Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis | Q43937884 | ||
| Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification | Q28505336 | ||
| Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10 | Q28509194 | ||
| Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin | Q28589898 | ||
| The ADAMTS metalloproteinases | Q29544428 | ||
| Histone acetylation and transcriptional regulatory mechanisms | Q29547707 | ||
| Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
| Matrix metalloproteinases and the regulation of tissue remodelling | Q29618747 | ||
| How matrix metalloproteinases regulate cell behavior | Q29620360 | ||
| Structure and function of matrix metalloproteinases and TIMPs | Q30014818 | ||
| Fibronectin fragment activation of proline-rich tyrosine kinase PYK2 mediates integrin signals regulating collagenase-3 expression by human chondrocytes through a protein kinase C-dependent pathway | Q30433820 | ||
| Absence of mechanical allodynia and Abeta-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase | Q33197078 | ||
| Structural basis for the highly selective inhibition of MMP-13. | Q33212333 | ||
| Insight into the structural determinants for selective inhibition of matrix metalloproteinases | Q33294553 | ||
| Matrix metalloproteinases: a tail of a frog that became a prince | Q33337157 | ||
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment | Q33540394 | ||
| Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cdelta pathways in human adult articular chondrocytes | Q33953872 | ||
| Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice | Q34346225 | ||
| Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis | Q34407611 | ||
| ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro | Q34407615 | ||
| Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis | Q34442331 | ||
| Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis | Q34600313 | ||
| ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. | Q34606492 | ||
| Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. | Q34607880 | ||
| Matrix metalloproteinases in arthritic disease | Q34731104 | ||
| Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis | Q34923078 | ||
| Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. | Q35048514 | ||
| Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects | Q35143905 | ||
| Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I | Q35669086 | ||
| Signaling pathways responsible for cancer cell invasion as targets for cancer therapy | Q35793957 | ||
| A review of depsipeptide and other histone deacetylase inhibitors in clinical trials | Q35848270 | ||
| Signaling transduction: target in osteoarthritis | Q35864727 | ||
| Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis | Q35953531 | ||
| Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy | Q36048379 | ||
| Kinomics: characterizing the therapeutically validated kinase space. | Q36169985 | ||
| Matrix metalloproteinases: role in arthritis | Q36251020 | ||
| MMPs and ADAMTSs: functional studies | Q36251025 | ||
| In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy | Q36255141 | ||
| NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta | Q36259805 | ||
| A history of the understanding of cartilage | Q36293638 | ||
| The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors | Q36368334 | ||
| ADAMTS proteinases: potential therapeutic targets? | Q36393546 | ||
| Antisense strategies in degenerative joint diseases: sense or nonsense? | Q36436056 | ||
| Novel functions of TIMPs in cell signaling | Q36471132 | ||
| Gene therapy for arthritis: what next? | Q36490241 | ||
| NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis | Q36490904 | ||
| Step into the groove: engineered transcription factors as modulators of gene expression. | Q36492700 | ||
| Understanding the role of tissue degrading enzymes and their inhibitors in development and disease | Q36596171 | ||
| Mitogen activated protein kinase inhibitors: where are we now and where are we going? | Q36622407 | ||
| Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression | Q36664362 | ||
| Collagenase gene regulation by pro-inflammatory cytokines in cartilage | Q36664366 | ||
| Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis | Q36678766 | ||
| Regulation of matrix metalloproteinase gene expression | Q36682744 | ||
| Molecular targets in osteoarthritis: metalloproteinases and their inhibitors | Q36737782 | ||
| Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis | Q36737786 | ||
| Emerging roles of cysteine cathepsins in disease and their potential as drug targets. | Q36740577 | ||
| Matrix metalloproteinases as valid clinical targets | Q36741438 | ||
| ADAMs in cancer cell proliferation and progression. | Q36758613 | ||
| The futility of current approaches to chondroprotection | Q36806523 | ||
| The therapeutic uses of chromatin-modifying agents | Q36822457 | ||
| The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. | Q36846901 | ||
| Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? | Q36892551 | ||
| Altered endochondral bone development in matrix metalloproteinase 13-deficient mice | Q37407318 | ||
| Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis | Q37491625 | ||
| Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering | Q38270327 | ||
| Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice | Q39904130 | ||
| Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). | Q40180627 | ||
| Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors | Q40284088 | ||
| Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. | Q40464079 | ||
| Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing | Q40609440 | ||
| Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. | Q40646766 | ||
| Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism | Q40773551 | ||
| Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown | Q40790873 | ||
| The AP-1 site and MMP gene regulation: what is all the fuss about? | Q41460650 | ||
| Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline | Q41853433 | ||
| Activity of matrix metalloproteinase-9 against native collagen types I and III. | Q42034412 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-18 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Metalloproteases as potential therapeutic targets in arthritis treatment | |
| P478 | volume | 12 |
| Q33607501 | ADAMTS-12: a multifaced metalloproteinase in arthritis and inflammation |
| Q37358225 | Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management? |
| Q51015488 | Cytokine-induced MMP13 Expression in Human Chondrocytes Is Dependent on Activating Transcription Factor 3 (ATF3) Regulation. |
| Q59804748 | Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) selectively contributes to MMP1 expression in human chondrocytes |
| Q37270886 | Degradome expression profiling in human articular cartilage |
| Q94093601 | Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor |
| Q38124278 | Epigenetic mechanisms and non-coding RNAs in osteoarthritis. |
| Q51017366 | In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors. |
| Q41963141 | Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms |
| Q39207621 | Matrix metalloproteinase 13 expression in response to double-stranded RNA in human chondrocytes. |
| Q39669677 | Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies |
| Q59333142 | Purification and enzymatic characterization of a novel metalloprotease from Lachesis muta rhombeata snake venom |
| Q64260627 | Recent advances in understanding the regulation of metalloproteinases |
| Q55023431 | Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology. |
| Q52688540 | Serine proteinases in the turnover of the cartilage extracellular matrix in the joint: implications for therapeutics. |
| Q37714909 | Small molecules for bone diseases |
| Q41785296 | Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors |
| Q42291702 | Targeted Fluoro Positioning for the Discovery of a Potent and Highly Selective Matrix Metalloproteinase Inhibitor |
| Q37358106 | The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases. |
| Q37825835 | The role of ADAMTSs in arthritis |
| Q47168535 | The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover |
Search more.